Elvire Tostivint-Pons
Nantes, France
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 61 publications
First-Line Sunvozertinib in NSCLC with EGFR Exon 20 Insertion Mutations.
Journal: The New England journal of medicine
Published: May 29, 2026
First-Line Sunvozertinib in NSCLC with EGFR Exon 20 Insertion Mutations.
Journal: The New England journal of medicine
Published: May 29, 2026
ILD with datopotamab deruxtecan combinations: a warning signal we should not ignore.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: May 12, 2026
ILD with Datopotamab Deruxtecan combinations: A warning signal we should not ignore.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: May 12, 2026
Automated extraction of temporalized tumor evolution from oncology EMRs using natural language processing.
Journal: ESMO real world data and digital oncology
Published: April 03, 2026
Corrigendum to 'Final Analysis Results and Patient-Reported Outcomes From DESTINY-Lung02-A Dose-Blinded, Randomized, Phase 2 Study of Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic NSCLC' [Journal of Thoracic Oncology Volume 20 Issue 12 (2025) 1814-1828].
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: February 23, 2026
Impact of Immune Checkpoint Inhibitor-Combined Chemotherapy as First-Line Treatment for Non-Small Cell Lung Cancer With Brain Metastases.
Journal: Clinical lung cancer
Published: January 28, 2026
PD-1 blockade does not enhance alloimmunization after allogeneic dendritic cell vaccination in cancer patients.
Journal: Frontiers in immunology
Published: December 08, 2025
Methylated circulating tumor DNA: technical challenges and clinical applications in non-small cell lung cancer patients-a narrative review.
Journal: Translational lung cancer research
Published: November 19, 2025
Evaluation of the return-to-work rate in systemically treated non-small cell lung cancer patient
Journal: Bulletin du cancer
Published: September 12, 2025
Unlocking the power of non-coding RNAs: toward real-time cancer monitoring in precision oncology.
Journal: Molecular cancer
Published: August 05, 2025
Final Analysis Results and Patient-Reported Outcomes From DESTINY-Lung02-A Dose-Blinded, Randomized, Phase 2 Study of Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic NSCLC.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: June 11, 2025
Last Updated: 09/26/2026